1
|
Bernal-Mizrachi E, Fatrai S, Johnson JD,
et al: Defective insulin secretion and increased susceptibility to
experimental diabetes are induced by reduced Akt activity in
pancreatic islet beta cells. J Clin Invest. 114:928–936. 2004.
View Article : Google Scholar : PubMed/NCBI
|
2
|
McKillop AM, Abdel-Wahab YH, Mooney MH,
O'Harte FP and Flatt PR: Secretion of glycated insulin from
pancreatic beta-cells in diabetes represents a novel aspect of
beta-cell dysfunction and glucose toxicity. Diabetes Metab.
28:3S61–3S69. 2002.PubMed/NCBI
|
3
|
Sesti G: Apoptosis in the beta cells:
cause or consequence of insulin secretion defect in diabetes? Ann
Med. 34:444–450. 2002. View Article : Google Scholar : PubMed/NCBI
|
4
|
Liu X, Liu L, Chen P, et al: Clinical
trials of traditional Chinese medicine in the treatment of diabetic
nephropathy - a systematic review based on a subgroup analysis. J
Ethnopharmacol. 151:810–819. 2014. View Article : Google Scholar : PubMed/NCBI
|
5
|
Wang J and Xiong X: Current situation and
perspectives of clinical study in integrative medicine in China.
Evid Based Complement Alternat Med. 2012:268–542. 2012. View Article : Google Scholar
|
6
|
Tong XL, Dong L, Chen L and Zhen Z:
Treatment of diabetes using traditional Chinese medicine: past,
present and future. Am J Chin Med. 40:877–886. 2012. View Article : Google Scholar : PubMed/NCBI
|
7
|
Xie W and Du L: Diabetes is an
inflammatory disease: evidence from traditional Chinese medicines.
Diabetes Obes Metab. 13:289–301. 2011. View Article : Google Scholar : PubMed/NCBI
|
8
|
Guo DZ, Wang YH, Bian D, Liu XR and Chen
ZQ: Effect of blood-activating and stasis-dissolving herbs on renin
angiotensin system in diabetic nephropathy rats. Zhong Yi Za Zhi.
1:75–78. 2010.(In Chinese).
|
9
|
Covington MB: Traditional Chinese medicine
in the treatment of diabetes. Diabetes Spectr. 14:154–159. 2001.
View Article : Google Scholar
|
10
|
Wang X, Zhang A and Sun H: Future
perspectives of Chinese medical formulae: chinmedomics as an
effector. OMICS. 16:414–421. 2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Ahmed N: Advanced glycation endproducts -
role in pathology of diabetic complications. Diabetes Res Clin
Pract. 67:3–21. 2005. View Article : Google Scholar : PubMed/NCBI
|
12
|
Song YZ, Song SW, Wu XM, et al: Effect of
therapy of strengthening Qi and nourishing Yin, removing stasis and
dredging collaterals on diabetic nephropathy: An observation of 46
cases. J New Chi Med. 3:232008.
|
13
|
Makita Z, Radoff S, Rayfield EJ, et al:
Advanced glycosylation end products in patients with diabetic
nephropathy. N Engl J Med. 325:836–842. 1991. View Article : Google Scholar : PubMed/NCBI
|
14
|
Miura J, Yamagishi Si, Uchigata Y, et al:
Serum levels of non-carboxymethyllysine advanced glycation
endproducts are correlated to severity of microvascular
complications in patients with Type 1 diabetes. J Diabetes
Complications. 17:16–21. 2003. View Article : Google Scholar : PubMed/NCBI
|
15
|
Ono Y, Aoki S, Ohnishi K, Yasuda T, Kawano
K and Tsukada Y: Increased serum levels of advanced glycation
end-products and diabetic complications. Diabetes Res Clin Pract.
41:131–137. 1998. View Article : Google Scholar : PubMed/NCBI
|
16
|
Shimoike T, Inoguchi T, Umeda F, Nawata H,
Kawano K and Ochi H: The meaning of serum levels of advanced
glycosylation end products in diabetic nephropathy. Metabolism.
49:1030–1035. 2000. View Article : Google Scholar : PubMed/NCBI
|
17
|
Rosmond R and Björntorp P: The
hypothalamic-pituitary-adrenal axis activity as a predictor of
cardiovascular disease, type 2 diabetes and stroke. J Intern Med.
247:188–197. 2000. View Article : Google Scholar : PubMed/NCBI
|
18
|
Fujisawa I, Nishimura K, Asato R, et al:
Posterior lobe of the pituitary in diabetes insipidus: MR findings.
J Comput Assist Tomogr. 11:221–225. 1987. View Article : Google Scholar : PubMed/NCBI
|
19
|
Vuksan V, Whitham D, Sievenpiper JL, et
al: Supplementation of conventional therapy with the novel grain
Salba (Salvia hispanica L.) improves major and emerging
cardiovascular risk factors in type 2 diabetes: results of a
randomized controlled trial. Diabetes Care. 30:2804–2810. 2007.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Li WL, Zheng HC, Bukuru J and De Kimpe N:
Natural medicines used in the traditional Chinese medical system
for therapy of diabetes mellitus. J Ethnopharmacol. 92:1–21. 2004.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Liu YN, Guo LZ, Wang LH, Zhang LQ and Deng
W: Experimental research on prevention and therapy of diabetic
nephropathy by means of boosting qi nourishing yin transforming
stasis and downgrade turbidity. Zhong Hua Zhong Yi Yao Xue Kan.
26:1711–1713. 2008.(In Chinese).
|
22
|
Colman PG, Thomas DW, Zimmet PZ, Welborn
TA, Garcia-Webb P and Moore MP: New classification and criteria for
diagnosis of diabetes mellitus. The Australasian Working Party on
Diagnostic Criteria for Diabetes Mellitus. NZ Med J. 112:139–141.
1999.
|
23
|
Weng WL: Clinical significance and
existing problems of hemorrheology. Zhong Guo Wei Xun Huan.
6:52002.(In Chinese).
|
24
|
Lv XF, Meng QY and Guo XM: Effect of
Rehmannia glutinosa water extraction on insulin resistance
and gene expression of resistin in type 2 diabetes mellitus rats.
Zhong Guo Zhong Yao Za Zhi. 32:2182–2184. 2007.(In Chinese).
|
25
|
Lee MS and Sohn CB: Anti-diabetic
properties of chrysophanol and its glucoside from rhubarb rhizome.
Biol Pharm Bull. 31:2154–2157. 2008. View Article : Google Scholar : PubMed/NCBI
|
26
|
Koya D, Haneda M, Nakagawa H, et al:
Amelioration of accelerated diabetic mesangial expansion by
treatment with a PKC beta inhibitor in diabetic db/db mice, a
rodent model for type 2 diabetes. FASEB J. 14:439–447.
2000.PubMed/NCBI
|
27
|
Schnackenberg CG and Wilcox CS: The SOD
mimetic tempol restores vasodilation in afferent arterioles of
experimental diabetes. Kidney Int. 59:1859–1864. 2001. View Article : Google Scholar : PubMed/NCBI
|
28
|
Berg TJ, Bangstad HJ, Torjesen PA, Osterby
R, Bucala R and Hanssen KF: Advanced glycation end products in
serum predict changes in the kidney morphology of patients with
insulin-dependent diabetes mellitus. Metabolism. 46:661–665. 1997.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Berg TJ, Snorgaard O, Faber J, et al:
Serum levels of advanced glycation end products are associated with
left ventricular diastolic function in patients with type 1
diabetes. Diabetes Care. 22:1186–1190. 1999. View Article : Google Scholar : PubMed/NCBI
|
30
|
Bolton WK, Cattran DC, Williams ME, et al:
Randomized trial of an inhibitor of formation of advanced glycation
end products in diabetic nephropathy. Am J Nephrol. 24:32–40. 2004.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Forbes JM, Cooper ME, Thallas V, et al:
Reduction of the accumulation of advanced glycation end products by
ACE inhibition in experimental diabetic nephropathy. Diabetes.
51:3274–3282. 2002. View Article : Google Scholar : PubMed/NCBI
|
32
|
Yin X, Zhang Y, Wu H, et al: Protective
effects of Astragalus saponin I on early stage of diabetic
nephropathy in rats. J Pharmacol Sci. 95:256–266. 2004. View Article : Google Scholar : PubMed/NCBI
|
33
|
Gu J, Zhang H, Chen L, Xu S, Yuan G and Xu
X: Drug-target network and polypharmacology studies of a
Traditional Chinese Medicine for type II diabetes mellitus. Comput
Biol Chem. 35:293–297. 2011. View Article : Google Scholar : PubMed/NCBI
|
34
|
Ji L, Tong X, Wang H, et al:
Evidence-Based Medical Research of Xiaoke Pill Study Group:
Efficacy and safety of traditional chinese medicine for diabetes: A
double-blind, randomised, controlled trial. PLoS One. 8:e567032013.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Tong XL, Dong L, Chen L and Zhen Z:
Treatment of diabetes using traditional Chinese medicine: Past,
present and future. Am J Chin Med. 40:877–886. 2012. View Article : Google Scholar : PubMed/NCBI
|